Data last refreshed 97 days ago — analysis may not reflect the latest market data

EMN

NEUTRAL

$74.25

P/E

18.14

PEG

FCF Yield

Rev Growth YoY

-671.0% YoY

Gross Margin

2109.0%

Health Score

4/10

D/E Ratio

0.80

Confidence

LOW


Advertisement

Business Snapshot

The ticker and exchange identifiers in this payload are blank, making a definitive business description impossible from the data alone. Based on available financial ratios — including a Price/Sales of 0.97x and a Price/Book of 1.22x — the company appears to be a relatively asset-light business trading near book value. Without confirmed market cap data, the capitalization tier cannot be determined with certainty.

Advertisement

Financial Health

Score: 4/10

The margin figures in this dataset are statistically anomalous and warrant extreme caution in interpretation: a reported gross margin of 2,109% and a net margin of 542% are almost certainly the result of data errors, accounting reclassifications, or unusual one-time items rather than genuine operational performance, and cannot be relied upon as indicators of underlying health. On the more credible side, a Debt/Equity ratio of 0.8x is manageable, and a current ratio of 1.37x suggests the company can meet near-term obligations...

Risk Assessment

  • DATA INTEGRITY: Revenue growth of -671% YoY and gross margin of 2,109% are statistically implausible, indicating possible data errors or extreme accounting distortions that make fundamental analysis unreliable.
  • EARNINGS QUALITY: The company beat earnings estimates in only 1 of its last 4 quarters, suggesting persistent shortfalls versus market expectations.
  • CASH FLOW: Free cash flow is unavailable, removing the single most important metric for assessing business sustainability and intrinsic value.
  • TECHNICALS: A confirmed death cross (50-day MA crossing below 200-day MA) is a bearish long-term price signal, compounded by a bearish MACD reading.
  • VALUATION UNCERTAINTY: With no DCF estimate, no PEG ratio, and no TTM Revenue or Net Income figures, there is no reliable framework to establish whether the current price of $74.25 is justified.

---...

**Score: 4/10** The margin figures in this dataset are statistically anomalous and warrant extreme caution in interpretation: a reported gross margin of 2,109% and a net margin of 542% are almost certainly the result of data errors, accounting reclassifications, or unusual one-time items rather than genuine operational performance, and cannot be relied upon as indicators of underlying health. On the more credible side, a Debt/Equity ratio of 0.8x is manageable, and a current ratio of 1.37x suggests the company can meet near-term obligations. However, the complete absence of Free Cash Flow data makes it impossible to assess whether the business is self-funding, which is a critical gap. ---

- **DATA INTEGRITY: Revenue growth of -671% YoY and gross margin of 2,109% are statistically implausible, indicating possible data errors or extreme accounting distortions that make fundamental analysis unreliable.** - **EARNINGS QUALITY: The company beat earnings estimates in only 1 of its last 4 quarters, suggesting persistent shortfalls versus market expectations.** - **CASH FLOW: Free cash flow is unavailable, removing the single most important metric for assessing business sustainability and intrinsic value.** - **TECHNICALS: A confirmed death cross (50-day MA crossing below 200-day MA) is a bearish long-term price signal, compounded by a bearish MACD reading.** - **VALUATION UNCERTAINTY: With no DCF estimate, no PEG ratio, and no TTM Revenue or Net Income figures, there is no reliable framework to establish whether the current price of $74.25 is justified.** ---

Unlock the full AI report

Full 8-section analysis includes:

Financial Health
Growth Momentum
Valuation Snapshot
Risk Flags
Sentiment & News
Technical Snapshot
Full Verdict with Confidence Rating
Last updated 2348 hours ago · Data sourced from FMP & Finnhub · Not financial advice